.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Cerilliant
Boehringer Ingelheim
Argus Health
Deloitte
Merck
AstraZeneca
Express Scripts
Cantor Fitzgerald
McKinsey

Generated: September 23, 2017

DrugPatentWatch Database Preview

LEXAPRO Drug Profile

« Back to Dashboard

What is the patent landscape for Lexapro, and when can generic versions of Lexapro launch?

Lexapro is a drug marketed by Forest Labs and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-five drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

Summary for Tradename: LEXAPRO

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list15
Bulk Api Vendors: see list68
Clinical Trials: see list75
Patent Applications: see list386
Drug Prices:see details
DailyMed Link:LEXAPRO at DailyMed

Pharmacology for Tradename: LEXAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-001Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
SOLUTION;ORAL021365-001Nov 27, 2002AARXYesYes► Subscribe► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-002Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-001Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-002Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-003Aug 14, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-003Aug 14, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LEXAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-001Aug 14, 2002► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-003Aug 14, 2002► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-002Aug 14, 2002► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
SOLUTION;ORAL021365-001Nov 27, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LEXAPRO

Drugname Dosage Strength RLD Submissiondate
escitalopram oxalateCapsules5 mgLexapro8/17/2005
escitalopram oxalateCapsules10 mg and 20 mgLexapro3/30/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Express Scripts
Federal Trade Commission
UBS
Novartis
Baxter
Colorcon
Merck
Deloitte
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot